For children diagnosed with aggressive brain tumors, research time matters. Pediatric high-grade gliomas (HGG), including diffuse midline gliomas (DMG), remain among the most difficult childhood brain tumors to study and treat. These tumors are fast-moving, devastating, and urgently in need of new research paths.
Yet for many researchers, the first step toward discovery often begins long before analysis. They must find the right data, gather it from different places, clean it, organize it, and connect it across data types before they can begin asking meaningful questions.
Now, CBTN Curated | HGG-DMG gives researchers a clearer starting point.
The Children’s Brain Tumor Network (CBTN) has launched a first-of-its-kind, openly accessible pediatric high-grade glioma data product now available in CAVATICA. CBTN Curated | HGG-DMG brings together harmonized clinical, genomic, and imaging data in one connected environment, giving researchers immediate access to research-ready data for HGG and a focused DMG subset.
“High-grade glioma is one of the most common brain tumors we see in pediatrics,” said David Higgins. “Within that broader group, diffuse midline glioma is especially important because these tumors share a common genetic disruption. That gives researchers a focused opportunity to study what these tumors have in common and where future treatment strategies may begin to emerge.”
DMG is a subtype of HGG that occurs in midline structures of the brain and spinal cord. Many DMG tumors are defined by a shared genetic alteration, which makes them a critical area of study for researchers working to better understand tumor biology and identify more precise approaches to treatment.
CBTN Curated | HGG-DMG positions DMG within the broader HGG research landscape while giving researchers a focused way to explore this shared biology across patients enrolled in CBTN.
The strength of the data product lies not only in the amount of data available but also in how the data has been prepared. High-quality clinical, genomic, and imaging data are connected in CAVATICA, allowing researchers to begin exploring relationships across data types without first rebuilding the foundation themselves.
For pediatric neuro-oncology researchers and clinicians, that preparation can make a meaningful difference. Data collection, harmonization, and cleanup can take months or even years. By making these steps easier, CBTN Curated | HGG-DMG helps researchers move more quickly from access to analysis.
“Researchers should be able to spend more time asking questions and less time preparing the data needed to ask them,” Higgins said. “This data product gives them a clearer starting point.”
CBTN Curated | HGG-DMG also reflects CBTN’s broader commitment to building a more connected pediatric brain tumor research ecosystem. Through CBTN, data from children across many institutions can be shared, organized, and transformed into resources that support discovery across the research community.
This model is especially important in rare and aggressive pediatric diseases, where no single institution can answer the biggest questions alone. By bringing data together and making it easier to use, CBTN helps create the conditions for researchers to learn from more children, more institutions, and more types of information.
The launch of CBTN Curated | HGG-DMG marks another step toward a scalable model for pediatric cancer data products. Each data product helps demonstrate how deeply curated, disease-focused data can be prepared once and used by many researchers, accelerating the path from shared data to shared discovery.
For children with HGG and the DMG sub-set, progress depends on researchers having the tools and data they need to move faster. CBTN Curated | HGG-DMG gives them a stronger place to begin.
Create a free CAVATICA account to view and explore CBTN Curated | HGG-DMG here.
